Zoledronic acid in the management of metastatic bone disease

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 261-268

  Polascik, Thomas J ^a   Mouraviev, Vladimir ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Advanced prostate cancer; Metastatic bone disease; Osteoporosis; Skeletal relevant events; Zoledronic acid

Indexed keywords

ANDROGEN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ARTHRALGIA; ASTHENIA; BACKACHE; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; GOLD STANDARD; HORMONAL THERAPY; HUMAN; HYPOCALCEMIA; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY TUBULE NECROSIS; LONG TERM CARE; LOW DRUG DOSE; MOUTH HYGIENE; MOUTHWASH; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; OSTEOLYSIS; OSTEOPOROSIS; PAIN; PATHOGENESIS; PREVENTIVE DENTISTRY; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION; TREATMENT INDICATION; VERTIGO;

EID: 41549094951     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Berenson JR. 2005. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist, 10:52-62.
2. Body JJ, Diel IJ, Lichinitzer M, et al. 2004. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo controlled phase III studies. Br J Cancer, 90:1133-7.
3. Body JJ, Diel IJ, Lichinitser MR et al. On behalf of the MF 4625 study group. 2003. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol, 14:1399-405.
4. Boissier S, Ferreras M, Peyruchaud O, et al. 2000. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res, 60:2949-54.
5. Boissier S, Magnetto S, Frappart L, et al. 1997. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res, 57:3890-4.
6. Casey R, Love W, Mendoza C, et al. 2006. Zoledronic acid reduces bone loss in men with prostate cancer undergoing androgen deprivation therapy. Presented at 2006 Multidisciplinary Prostate Cancer Symposium. February 24-26, 2006; San Francisco, Calif. Abstract #184.
7. Clemons MJ, Dranitsaris G, Ooi WS, et al. 2006. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event for progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol, 24:4895-900.
8. Coleman RE, Major P, Lipton A, et al. 2005. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol, 23:4925-35.
9. Cummings SR, Bates D, Black DM. 2002. Clinical use of bone densitometry: scientific review. JAMA, 288:1889-97.
10. Daniell HW. 1997. Osteoporosis after orchiectomy for prostate cancer. J Urol, 157:439-44.
11. Faulkner KG. 2000. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res, 15:183-7.
12. Flanigan RC, Campbell SC, Clark JI, et al. 2003. Metastatic renal cell carcinoma. Curr Treat Options Oncol, 4:385-90.
13. Garnero P, Buchs N, Zekri J, et al. 2000. Markers of bone turnover for the management of patients with bone metastases form prostate cancer. Br J Cancer, 82:858-64.
14. Green JR, Muller K, Jaeggi KA. 1994. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res, 9:745-51.
15. Harada M, Iida M, Yamaguchi M, et al. 1992. Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol, 324:173-82.
16. Higano CS. 2004. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin N Am, 31:331-52.
17. Higano CS. 2003. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol, 21:392-8.
18. Hoff AO, Toth B, Altundag K, et al. 2006 Osteonecrosis of the Jaw in Patients Receiving Intravenous Bisphosphonate Therapy. JCO, 24(suppl 1):8528.
19. International Osteoporosis Foundation. The facts about osteoporosis and its impact [online]. Accessed January 10, 2007. URL: http://www.iofbonehealth.org/facts.
20. Israeli RS, Rosenberg S, Saltzstein D, et al. 2006. Bone mineral density in patients with prostate cancer undergoing initial androgen-deprivation therapy. J Urol, 175(Suppl 4):134. Abstract 410.
21. Kohno N, Aogi K, Minami H, et al. 2005. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol, 23:3314-21.
22. Kristensen B, Ejlertsen B, Groenvold M, et al. 1999. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med, 246:67-74.
23. Lipton A. 2004. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol, 2:205-213.
24. Lipton A, Theriault R, Hortobagyi G, et al. 2000. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized controlled trials. Cancer, 88:1082-90.
25. McKiernan JM, Delea TE, Liss M, et al. 2004. Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases. Proc Am Soc Clin Oncol, 23:531, A6057.
26. Martel CL, Lara PN. 2003. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol, 45:177-90.
27. Michaelson MD, Lee H, Kaufman DS, et al. 2006. Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized placebo-controlled trial. J Clin Oncol, 24(18S pt 1):220s. Abstract #4515.
28. Oefelein MG, Ricchiuti V, Conrad W, et al. 2002. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol, 168:1005-7.
29. Polascik TJ, Given RW, Metzer C, et al. 2005. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology, 66:1054-9.
30. Plunkett TA, Smith P, Rubens RD. 2000. Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer, 36:476-82.
31. Rosen LS, Gordon DH, Dugan W, et al. 2004a. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer, 100:36-43.
32. Rosen LS, Gordon D, Kaminski M, et al. 2001. Zoledronic acid versus palmidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer, J 7:377-87.
33. Rosen LS, Gordon D, Kaminski M, et al. 2003. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 98:1735-44.
34. Rosen LS, Gordon D, Tchekmedyian NS, et al. 2004b. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III double-blind, placebo-controlled trial. Cancer, 100:2613-21.
35. Ross RW, Small EJ. 2002. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol, 167:1952-6.
36. Ryan CW, Huo D, Demers LM, et al. 2006. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol, 176:972-8.
37. Saad F, Gleason DM, Murray R, et al. 2002. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst, 94:1458-68.
38. Saad F, Gleason DM, Murray R, et al. 2004. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst, 96:879-82.
39. Saad F, Lipton A. 2005. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Internat, 96:964-9.
40. Sabbatini P, Larson SM, Kremer A, et al. 1999. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol, 17:948-57.
41. Shahinian VB, Kuo YF, Freeman JL, et al. 2005. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med, 352:154-64.
42. Small EJ, Smith MR, Seaman JJ, et al. 2003. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol, 21:427784.
43. Smith MR, Boyce SP, Moyneur E, et al. 2006. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol, 175:136-9.
44. Smith MR, Eastham J, Gleason DM, et al. 2003. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol, 169:2008-12.
45. Smith MR, Lee WC, Brandman J, et al. 2005. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol, 23:7897-903.
46. Smith MR, McGovern FJ, Zietman AL, et al. 2001. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 345:948-55.
47. Soloway MS, Hardeman SW, Hickey D, et al. 1988. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61:195-202.
48. The NCCN (2.2005) Prostate Cancer Clinical Practice Guidelines in Oncology© 2006 National Comprehensive Cancer Network, Inc. URL: http://www.nccn.org.
49. Wardley A, Davidson N, Barrett-Lee P, et al. 2005. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomized, crossover study of community vs hospital bisphosphonate administration. Br J Cancer, 92:1869-76.
50. Wegner H. 2006. Clinical experience with zoledronic acid: a urologist's perspective. Eur Urol Suppl, 5:551-2.
51. Weinfurt KP, Castel LD, Li Y, et al. 2004. Health-related quality of life among patients with breast cancer receiving zoledronic acid or palmidronate disodium for metastatic bone lesions. Medical Care, 42:164-75.
52. Weinfurt KP, Li Y, Castel LD, et al. 2002. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer. Ann Oncol, 13:180.
53. Weinfurt KP, Li Y, Castel LD, et al. 2005. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol, 16:579-84.
54. Zekri J, Ahmed N, Coleman RE, et al. 2001. The skeletal metastatic compications of renal cell carcinoma. Int J Oncol, 19:379-82.
55. Zometa® [package insert]. 2006. East Hanover, NJ; Novartis Pharmaceuticals Corporation.